Abstract
Introduction
Hypereosinophilia refers to persistent eosinophilia of >1,500/mm 3 of blood for more than six months. Hypereosinophilic syndrome (HES) refers to hypereosinophilia associated with eosinophilmediated organ damage. ¹Eosinophil-mediated organ damage includes cardiomyopathy, endomyocardial fibrosis, cutaneous lesions, sinusitis, pneumonitis, neuritis, gastroenteritis and vasculitis. ² , ³ In addition, there are few case reports on eosinophilic pancreatitis, ascites, thromboembolic complications, hepatosplenomegaly. 4 Secondary eosinophilia is the most frequent cause of peripheral blood eosinophilia. Primary eosinophilia is either clonal or idiopathic/ unexplained. Idiopathic HES is considered when both secondary and clonal eosinophilia is ruled out as a possibility.¹
Case Report
A 22-year old woman presented with 7-day history of sudden onset severe epigastric pain which was constant, aggravated by taking food and radiating to back. Pain was associated with nausea and several episodes of vomiting and managed conservatively. After few days she noticed gradual abdominal distension without pedal edema or facial puffiness. She had no history of joint pain, oral ulcer, skin rash, fever or weight loss.
She had similar type of pain 1 year back. She had recurrent sinusitis and chronic non productive cough for 3 years. She had no family history of atopy or such illness. Her previous CBC revealed total count 22,490/ mm 3 with 51% eosinophils (AEC-11,470/ mm 3 ).
On examination, her pulse was 110/min regular, blood pressure 110/70 mm Hg, non-icteric, non-oedematous, JVP was not raised. Abdomen examination revealed ascites with no organomegaly. Examination of other systems revealed only right sided pleural effusion. A clinical diagnosis of acute pancreatitis with ascites and right sided pleural effusion was made.
CBC revealed Hb 13.7gm/dl, TLC 25,000/ mm 3 with 40% eosinophil. Serum amylase and lipase done on 7 th day of abdominal pain was normal. Urine amylase was 760 U/L (normal < 360 U/L). Her serum calcium, albumin, SGPT, creatinine, electrolytes, sugar and lipid profile were normal. CRP was14.43 mg/L. CXR revealed bilateral pleural effusion ( fig.1 ). Abdominal sonography revealed only moderate ascites & bilateral pleural effusion ( fig.2 ). Ascitic fluid was straw coloured and study revealed total count 9000/mm 3 , (95% neutrophil, 5% lymphocyte, no malignant cell), albumin 27 gm/L, SAAG 7 gm/L and normal glucose, ADA, amylase level.
ANA, Anti-ds-DNA, c-ANCA, p-ANCA, hepatitis viral markers were negative. Urine R/E and Stool R/E were normal, and ICT for filaria was negative. Serum IgE was 2611.31 IU/ml (adult <100 IU / ml). CT scan of abdomen with contrast showed huge ascites with bilateral pleural effusion, pancreas normal in morphology, mostly uniform mild thickening of gastric antrum and mild thickening of anti-mesenteric wall of the dilated intestinal coils -possibly gastritis and enterocolitis (fig 3) . Endoscopy of upper GIT and Echocardiography were normal. Bone marrow study showed hyperactive granulopoiesis, shift to left, predominant eosinophilic myelocyte, no evidence of malignancy or parasitic infestation. Bone marrow cytogenetic study including BCR-ABL gene product were negative. FISH (fluorescence in situ hybridization) showed negative for PDGFR beta gene rearrangement or 5q32-33; negative FIP1L1-PDGFR alpha gene rearrangement or 4q12 (found in chronic eosinophilic leukemia). As neither secondary nor clonal cause was found, this case was diagnosed as an idiopathic hypereosinophilic syndrome. She was treated with tablet prednisolone 40mg daily for 2 weeks then gradually tapered. Patient's condition improved with decreasing abdominal pain, vomiting and ascites. CBC was done after 2 days of starting of prednisolone showed normal total WBC count (10,000/ mm 3 ) with 1% eosinophil (AEC-90/ mm 3 ). Ultrasound of abdomen after 1 week revealed no ascites.
Discussion
Primary eosinophilia is classified as clonal or idiopathic. Diagnosis of clonal eosinophilia requires morphologic, cytogenetic or molecular evidence of a myeloid neoplasm. Examples of clonal eosinophilia include eosinophilia associated with acute myeloid leukemia, MDS, CML, mastocytosis. Myeloid neoplasmassociated eosinophilia also includes the WHO MPN subcategory of chronic eosinophilic leukaemia, not otherwise specified (CEL-NOS).¹ Idiopathic Hypereosinophilic Syndrome (HES) is diagnosed when both secondary and clonal eosinophilia are ruled out as a possibility. 2 The symptoms are variable and related to the organs involved.The common organ systems involved are hematologic (100%), cardiovascular (58%), cutaneous (56%), neurologic (54%), pulmonary (49%), splenic (43%), hepatic (30%), ocular (23%), gastrointestinal (23%). 4 Gastrointestinal tract involvement can accompany HES and 20% of patients at some time may have diarrhea. 5, 6, 7 Eosinophilic gastritis, enterocolitis, or colitis may be present. [8] [9] [10] [11] Pancreatitis and sclerosing cholangitis occur rarely. 7, 8 Hepatic involvement with HES includes chronic active hepatitis 12, 13 and the Budd-Chiari syndrome from hepatic vein obstruction. 14 In this case there is hematological, pulmonary, pancreatic, ascites and gastrointestinal tract involvement.
Idiopathic HES is a diagnosis by exclusion, thus all other possible causes of eosinophilia have to be ruled out before making a certain diagnosis.The diagnostic workup must include peripheral blood screening for mutation of FIP1L1-PDGFRA (alpha) and PDGFRB (beta) mutations using fluorescence in situ hybridization (FISH). This is crucial before diagnosis of idiopathic HES because clonal eosinophilia is easily treated with imatinib. If mutations are negative bone marrow examination for cytogenetic studies is indicated to rule out other myeloid malignancy.¹ Glucocorticoids are the cornerstone of therapy in idiopathic HES. Treatment with oral prednisolone is usually started at 1 mg/kg per day and continued for 1-2 weeks before the dose is tapered slowly over the ensuing 2-3 months. If symptoms recur at a prednisolone dose level of >10 mg / day, either hydroxyurea or interferon alpha is used as steroid-sparing agent.In patients who do not respond to usual therapy as outlined above, mepolizumab, alemtuzumab might be considered. Mepolizumab targets interlukin-5 (IL-5), a well recognizd survival factor for eosinophils. Alemtuzumab targets the CD52 antigen,which has been shown to be expressed by eosinophils but not by neutrophils.¹
Conclusion
Persistent peripheral blood eosinophilia demands further evaluation to diagnose the underlying cause and to identify eosinophil-mediated organ damage. Our patient had eosinophilia for more than 1 year and presented to us with a very unusual organ involvement i.e. pancreatitis with ascites. High index of suspicion is required for early diagnosis and treatment, by which we can reduce morbidity and mortality.
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